Notícias

MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.

ECL's strong Q1 earnings, digital growth and expanding high-tech platform support long-term upside despite rising cost pressures.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.

Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.

West Pharmaceutical Services (WST) stock has drawn attention after recent share price moves, with investors weighing its role in drug containment and delivery in relation to current valuation signals and recent returns over the past month and past 3 months. See our latest analysis for West Pharmaceutical Services. At a share price of $327.95, West Pharmaceutical Services has seen strong momentum build over the past quarter, with a 35.85% 3 month share price return and a 52.46% 1 year total...

TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.

BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.

Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.

COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.

COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

West Pharmaceutical Services recently reported strong first-quarter 2026 results, highlighting robust growth in biologics-related high-value components and self-injection delivery devices, and raised its full-year 2026 revenue and adjusted EPS guidance. The company emphasized its role as a critical part of injectable-drug infrastructure rather than a conventional packaging supplier, underlining how its specialized high-value products support complex biologic therapies. Next, we’ll examine...

QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.

GE HealthCare expands its Carilion Clinic collaboration with AAMP and Encompass to improve equipment management and operational efficiency across Virginia.

West Pharmaceutical continues to outpace broader market gains on strong earnings momentum and supportive analyst sentiment.

Stryker faces cyberattack fallout, but strong procedure demand, record Mako adoption and global expansion continue to support long-term growth.

VEEV's UCB pharmacovigilance deal expands Safety Suite adoption, supporting automation, compliance and long-term growth opportunities.

HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.

OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.

SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.

HNGE expands HingeSelect to include orthopedic surgery, aiming to deliver coordinated end-to-end MSK care from imaging to post-op recovery.

10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.